Description

PSMA-ALB-56 is a PSMA-targeting radioligand designed by combining the glutamate-urea PSMA-binding entity and an albumin binder[1].–20°C (Powder, sealed storage, away from moisture)-Applications-Cancer-programmed cell death-Formula-C66H95N11O18-Citation–References-[1]Umbricht CA, et al. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy. Mol Pharm. 2018;15(6):2297-2306.-CASNumber-2306049-48-7-MolecularWeight-1330.52-Compound Purity-98.92-SMILES-O=C([C@H]1CC[C@@H](CC1)CNC([C@H](CCCCNC(CCCC2=CC=C(C=C2)C)=O)NC(CN3CCN(CCN(CCN(CC3)CC(O)=O)CC(O)=O)CC(O)=O)=O)=O)N[C@H](C(NCCCC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O)=O)CC4=CC5=C(C=CC=C5)C=C4-Research_Area-Cancer-Solubility-10 mM in DMSO-Target-Drug-Linker Conjugates for ADC-Isoform-Traditional Cytotoxic Agents-Pathway-Antibody-drug Conjugate/ADC Related-MCE Product type-ADC Related